Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
One-third of new patients starting on oral GLP-1 weight-loss medications are taking Eli Lilly drug Foundayo, according to company Chief Executive Officer Dave Ricks. The strong market adoption comes as the drugmaker actively ramps up production to meet surging demand in the lucrative obesity and weight-loss treatment sector. Alongside the commercial performance of its pill, Eli Lilly announced broader portfolio strength, noting that 70 percent of 700,000 new seniors starting GLP-1 medications following Medicare coverage are using Lilly products. To support long-term manufacturing needs, the company broke ground on a massive facility in Houston.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ One-third of new GLP-1 pill patients are taking Foundayo, according to Eli Lilly CEO Dave Ricks.
- ✓ Foundayo has captured over 30% of new US patients on oral weight-loss drugs.
- ✓ Eli Lilly broke ground on a $6.5 billion plant in Houston.
- ✓ Seventy percent of 700,000 new seniors who started GLP-1s after Medicare coverage are on Lilly drugs, according to the CEO.
What changed
Eli Lilly leadership provided updated sales figures showing Foundayo capturing over 30 percent of new U.S. oral weight-loss patients while breaking ground on a manufacturing facility in Houston.
Live updates
-
Eli Lilly CEO Reports Strong Initial Uptake for Foundayo
One-third of new patients starting on oral GLP-1 weight-loss medications are taking Eli Lilly drug Foundayo, according to company Chief Executive Officer Dave Ricks. The strong market adoption comes as the drugmaker actively ramps up production to meet surging demand in the lucrative obesity and weight-loss treatment sector. Alongside the commercial performance of its pill, Eli Lilly announced broader portfolio strength, noting that 70 percent of 700,000 new seniors starting GLP-1 medications following Medicare coverage are using Lilly products. To support long-term manufacturing needs, the company broke ground on a massive facility in Houston.
Why it matters
The weight-loss drug market has expanded rapidly, prompting heavy investments and infrastructure buildouts from major developers. Eli Lilly is investing billions of dollars in new production sites across the United States to secure supply chains for its popular therapies. These manufacturing expansions aim to address chronic supply constraints that have historically affected the entire class of incretin-based treatments.
What is confirmed
- One-third of new GLP-1 pill patients are taking Foundayo, according to Eli Lilly CEO Dave Ricks.
- Foundayo has captured over 30% of new US patients on oral weight-loss drugs.
- Eli Lilly broke ground on a $6.5 billion plant in Houston.
- Seventy percent of 700,000 new seniors who started GLP-1s after Medicare coverage are on Lilly drugs, according to the CEO.
What to watch next
- Expansion of Foundayo into foreign markets as noted by CEO Dave Ricks
- Progress on the Houston manufacturing facility slated for 2030
confidence 100%Sources used for this update (13)
- CNBC — Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Reuters — Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
- Investing.com — Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up By Reuters
- TipRanks — Eli Lilly Stock (LLY) Rises After Company Provides Update on Obesity Pill Sales
- TradingView — Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets
- KHOU — Eli Lilly is breaking ground in Houston on a facility planned for 2030
- houstonchronicle.com — The company behind a new GLP-1 pill is betting $6.5 billion on Houston
- qz.com — Lilly CEO Dave Ricks says Foundayo winning new pill patients
- Reuters — Weight-loss drug developers line up to tap lucrative market as competition heats up
- Axios — Eli Lilly breaks ground on $6.5B Houston plant
- CNBC — Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
- abc13.com — Lilly breaks ground in Generation Park, announces $15M contribution to San Jacinto College
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community